Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase II Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity’s Lead Drug Candidate

Intensity Therapeutics, Inc. announced that the company executed a collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK to conduct a Phase II randomized, controlled trial evaluating clinical and biological effects of intratumoral INT230-6 followed by the standard of care (SOC) immuno/chemotherapy vs. SOC immune/chemotherapy alone in early-stage triple-negative breast cancer in 54 patients in Switzerland.